Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes by Gislason, Gunnar H et al.
Persistent Use of Evidence-Based Pharmacotherapy in Heart
Failure Is Associated With Improved Outcomes
Gunnar H. Gislason, MD; Jeppe N. Rasmussen, MD; Steen Z. Abildstrom, MD, PhD;
Tina Ken Schramm, MD; Morten Lock Hansen, MD; Pernille Buch, MD; Rikke Sørensen, MD;
Fredrik Folke, MD; Niels Gadsbøll, MD, DMSc; Søren Rasmussen, PhD; Lars Køber, MD, DMSc;
Mette Madsen, MSc; Christian Torp-Pedersen, MD, DMSc
Background—Undertreatment with recommended pharmacotherapy is a common problem in heart failure and may
influence prognosis. We studied initiation and persistence of evidence-based pharmacotherapy in 107 092 patients
discharged after first hospitalization for heart failure in Denmark from 1995 to 2004.
Methods and Results—Prescriptions of dispensed medication and mortality were identified by an individual-level linkage
of nationwide registers. Inclusion was irrespective of left ventricular function. Treatment with renin-angiotensin
inhibitors (eg, angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers), -blockers, spironolac-
tone, and statins was initiated in 43%, 27%, 19%, and 19% of patients, respectively. Patients who did not initiate
treatment within 90 days of discharge had a low probability of later treatment initiation. Treatment dosages were in
general only 50% of target dosages and were not increased during long-term treatment. Short breaks in therapy were
common, but most patients reinitiated treatment. Five years after initiation of treatment, 79% patients were still on
renin-angiotensin inhibitors, 65% on -blockers, 56% on spironolactone, and 83% on statins. Notably, multiple drug
treatment and increased severity of heart failure was associated with persistence of treatment. Nonpersistence with
renin-angiotensin inhibitors, -blockers, and statins was associated with increased mortality with hazard ratios for death
of 1.37 (95% CI, 1.31 to 1.42), 1.25 (95% CI, 1.19 to 1.32), 1.88 (95% CI, 1.67 to 2.12), respectively.
Conclusions—Persistence of treatment was high once medication was started, but treatment dosages were below
recommended dosages. Increased severity of heart failure or increased number of concomitant medications did not
worsen persistence, but nonpersistence identified a high-risk population of patients who required special attention. A
focused effort on early treatment initiation, appropriate dosages, and persistence with the regimen is likely to provide
long-term benefit. (Circulation. 2007;116:737-744.)
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Treatment with inhibitors of the renin-angiotensin system(RASi; eg, angiotensin-converting enzyme inhibitors and an-
giotensin-2 receptor blockers), -blockers, and spironolac-
tone are the cornerstones of modern medical management
of heart failure (HF) with reduced left ventricular ejection
fraction.1 Additionally, many of these patients may benefit
from statin treatment.2,3 Nevertheless, surveys have demon-
strated substantial underuse of these medications, and unde-
ruse has been associated with adverse events and impaired
prognosis.4–6 Comprehensive studies of the nature of under-
use are necessary to know whether underuse is caused by lack
of initiation, underdosing, or early discontinuation. Also,
multiple drug treatment is perceived to reduce persistence of
treatment, but this issue has only been partly explored in HF.
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In the present study we analyzed the medical treatment of
all 107 092 Danish patients who survived a first hospitaliza-
tion for HF between 1995 and 2004. We studied time to
initiation of treatment after discharge, used dosages, persis-
tence of treatment, and the effect of polypharmacy and
disease severity on persistence. Furthermore, we analyzed the
association between persistence of treatment and mortality.
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Methods
The Danish Data Protection Agency approved the present study (No.
2003541269). No ethical approval is required for retrospective
registry studies in Denmark.
Population
Patients 30 years of age who were discharged alive between 1995
and 2004 after their first hospitalization for HF (International
Classification of Diseases, 10th Revision [ICD-10] codes I11.0, I50,
I42, and J81 as primary or secondary diagnosis) were identified in
the Danish National Patient Registry, which registers all hospitaliza-
tions in Denmark since 1978. Each hospitalization is registered with
1 primary diagnosis and appropriate secondary diagnoses according
to ICD-10 (before 1994, ICD-8). To ensure a homogenous history of
patients, we required that the HF hospitalization was the first within
a 17-year period. Each patient’s vital status as of December 31, 2004,
was obtained from the Central Population Registry.
Medical Treatment
The Danish Registry of Medicinal Product Statistics registers all
prescriptions dispensed from Danish pharmacies since 1995. In Den-
mark the national health security system covers all inhabitants and
partially reimburses drug expenses (with a maximum copayment for
each individual ofUS $500 a year). Therefore pharmacies are required
to register all prescriptions dispensed, which ensures complete registra-
tion, and the reimbursement results in minimal incentive for patients to
obtain medication through other sources. Coding is according to the
Anatomic Therapeutical Chemical (ATC) system. The registry includes
information about date of dispensing, strength and formulation, quantity
dispensed, and the affiliation of the doctor who issues the prescription.
We defined initiation of treatment if prescriptions were claimed as
follows: RASi (ie, angiotensin-converting enzyme inhibitors and
angiotensin-2 antagonists; ATC C09), -blockers (ATC C07), and
spironolactone (ATC C03D) within 90 days from discharge, and statins
(ATC C10AA) within 180 days from discharge. Treatment status up to
6 months before hospitalization was determined for all drugs.
To quantify the severity of HF in the statistical models, patients
were classified into 4 groups according to the average daily dosage
of loop-diuretics (ATC C03C) during the first 90 days after discharge
(furosemide-equivalent dosage: furosemide 40 mgbumetanide 1
mg): Group I, 0 to 39 mg; Group II, 40 to 80 mg; Group III, 81 to
160 mg; and Group IV,160 m). In multivariable analysis there was
a linear trend between dosage of loop-diuretic and mortality
(P0.0001), which is in accordance with other studies.7 Pharmaco-
logically treated diabetes was identified from prescriptions of hypo-
glycemic medication such as oral or insulin (ATC A10) 90 days
before admission to 90 days after discharge.
Persistence of Treatment and Dosage
Persistence of treatment was estimated by identification of subsequent
prescription claims. Nonpersistence was defined as a break in therapy of
90 days among patients who survived for at least 90 days after
discontinuation of therapy. As another measure of persistence we
studied the proportion of patients alive who were on treatment on each
day. These methods have been described in details previously.8 Dosages
used were calculated and compared with recommended target dosages.1
Statistical Analysis
Times from hospital discharge to initiation of therapy were evaluated
with Kaplan-Meier estimators (censored for death). Trends in treat-
ment initiation and mortality across calendar years were examined
with logistic regression models, which included the calendar year as
a continuous variable. Multivariable analyses of time to first break in
therapy of 90 days and mortality were performed with Cox
proportional hazard models. All models were adjusted for age,
gender, calendar year, severity of HF, concomitant medical treat-
ment, and comorbidity (Table 1). Furthermore, in the analysis of
mortality, breaks in therapy of 90 days were included in the
proportional hazard models as a time-dependent covariate, which
indicated that patients were only considered at risk during breaks in
treatment that extended beyond 90 days. Model assumptions, such as
linearity of continuous variables, the proportional hazard assump-
tion, and lack of interactions, were tested and found valid unless
TABLE 1. Baseline Characteristics
Characteristics N %
Total patients (mean ageSD, y) 107 092 (74.811.6)
Male (mean ageSD, y) 55 368 (72.311.7) 51.7
Female (mean ageSD, y) 51 724 (77.610.8) 48.3
Year of first hospitalization for HF
1995 to 1996 19 789 18.5
1997 to 1998 19 996 18,6
1999 to 2000 22 588 21.1
2001 to 2002 23 257 21.7
2003 to 2004 21 462 20.1
Discharge diagnosis at first HF
hospitalization (ICD-10)
Hypertensive HF (I11.0) 2 605 2.4
Cardiomyopathy (I42) 4 418 4.1
Decompensated HF (I50.0 to I50.1) 32 736 30.7
Unspecified HF (I50.9) 64 024 59.8
Acute pulmonary edema (J81.9) 3 309 3.1
Familial status
Living alone 58 102 54.3
Comorbidity
MI at index admission for HF 9 246 8.6
History of prior MI 26 053 24.3
Cerbrovascular disease 7 982 7.5
Peripheral vascular disease 2 736 2.6
Diabetes with complications 5 862 5.5
Malignancy 4 034 3.8
Cardiac dysrhythmias 28 709 26.8
Renal failure 3 272 3.1
COPD 16 534 15.4
Severity group*
Group I 26 543 24,8
Group II 42 547 39.7
Group III 24 817 23.2
Group IV 13 185 12.3
Treatment
-Blocker† 29 084 27.2
RASi† 46 191 44.1
Spironolactone† 20 166 18.8
Statin‡ 13 084 12.2
Antidiabetics§ 13 387 12.5
Loop-diuretics§ 86 636 80.9
ICD-10 indicates International Classification of Diseases, 10th Revision;
COPD, chronic obstructive pulmonary disease.
*According to average daily dosage of loop-diuretic (furosemide) in the first
90 days after discharge (Group I, 0 to 39 mg; Group II, 40 to 80 mg; Group III,
81 to 160 mg; Group IV, 160 mg).
†At least 1 prescription claimed within 90 days from discharge.
‡At least 1 prescription claimed within 180 days from discharge
§At least 1 prescription claimed between 90 days before admission and 90
days after discharge.
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otherwise indicated. All analyses were performed with SAS soft-
ware, version 9.1 (SAS Institute, Cary, NC).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
There were 122 663 patients with a first hospitalization for
HF from 1995 to 2004; 107 092 (87.3%) patients were
discharged alive and included in the present study. A total of
123 (0.1%) patients were lost to follow-up (emigrated) and
were censored at the time of disappearance. Baseline charac-
teristics are shown in Table 1.
Medical Treatment
Initiation of treatment is depicted in Figure 1. At least 1
prescription of RASi within 90 days from discharge was claimed
by 46 191 (43.1%) patients (35.9% in 1995 and 49.6% in 2004;
P0.0001). The corresponding figures were 29 084 (27.2%)
patients for -blockers (12.1% in 1995 and 42.7% in 2004;
P0.0001), 20 166 (18.8%) patients for spironolactone (9.8% in
1995 and 24.9% in 2004; P0.0001), and 13 084 (12.2%)
patients for statins (2.0% in 1995 and 26.9% in 2004;
P0.0001). -Blockers documented for the treatment of HF
(ie, carvedilol, metoprolol [mainly metoprolol-succinate], and
bisoprolol) comprised 76.7% of all -blockers used, an
increase from 46.3% in 1995 to 93.9% in 2004 (P0.0001).
Of those patients who claimed a prescription within 90 days
of discharge, 44.0%, 46.4%, 23.9%, and 52.9% were treated
with a RASi, -blocker, spironolactone, or statin, respec-
tively, before admission. For patients who initiated treatment
within 90 days of discharge, 75% to 82% of the prescriptions
were issued by a hospital physician, and for patients who
started later prescriptions were equally distributed among
general practitioners and hospital physicians. For all drugs
under study, treatment was started within the first few months
and rarely started later (Figure 2).
Dosages
There was a considerable underdosing of RASi and
-blockers compared with recommended target dosages (Ta-
ble 2).1 Furthermore, dosages were likely to remain un-
changed from start of treatment onward except for carvedilol,
which was uptitrated as recommended.
Persistence of Treatment
Breaks in treatment of short duration were common, but the
majority of patients reinitiated treatment (Table 3). The multi-
variable Cox proportional hazard analysis showed that persis-
tence of -blocker and spironolactone treatment improved
through the period (Table 4). Men had poorer spironolactone
persistence than women, but higher persistence of RASi. In-
creasing age was associated with lower persistence of RASi,
spironolactone, and statins. Patients who lived alone generally
had lower persistence of treatment than patients who lived with
a partner. Concomitant use of spironolactone and RASi was
associated with lower persistence of treatment, compared with
patients who received only 1 of these drugs. Multiple concom-
itant medications were associated with increased persistence of
RASi, -blockers, and statins. There was an interaction between
age and number of concomitant drugs (P0.0001) for spirono-
lactone. Age-stratified analysis demonstrated only significant
difference in persistence of spironolactone treatment among
patients 75 years old (P0.0001). Patients who received
treatment prior to the HF admission had higher persistence of
treatment compared with patients who had not previously
received treatment. Patients who received higher dosages of a
loop-diuretic (a proxy for severity of HF) did not have poorer
persistence with any of the drugs. The persistence of treatment is
depicted in Figure 3. After 5 years of treatment 79%, 65%, 56%,
and 83% still used RASi, -blockers, spironolactone, and statins.
Mortality
The in-hospital-mortality fell from 14.5% in 1995 to 11.1% in
2004 (P0.0001) and the 1-year mortality fell from 38.7% to
34.5% (1995 to 2003; P0.0001). Except for spironolactone,
nonpersistence with RASi, -blockers, and statins was asso-
ciated with increased mortality (Table 5). We repeated the
analysis in subgroups according to whether the discharge
Figure 1. Patients who survived first HF hospitalization and
claimed a prescription of RASi, -blockers, or spironolactone
within 90 days or statin within 180 days from discharge.
Figure 2. Cumulative frequency of patients who survived first
HF hospitalization and claimed at least 1 prescription of
-blocker, RASi, spironolactone, or statin within the first year
after discharge (censored for death).
Gislason et al Persistence of Pharmacotherapy in HF 739
 by guest on January 11, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
coding of HF was listed as primary or secondary diagnosis
and found no differences in outcome.
Discussion
The present nationwide study addresses initiation and persis-
tence of evidence-based pharmacological treatment among an
unselected cohort of patients with HF. The study has the
following main findings: 1) treatment is usually initiated shortly
after discharge and relatively few patients initiate treatment later;
2) if treatment is initiated early, persistence of treatment is high;
3) dosages used are generally far below recommended dosages
and rarely uptitrated during long-term treatment; 4) increased
severity and increased number of concomitant medications are
associated with high persistence of treatment; and 5) nonpersis-
tence with pharmacological treatment in HF identifies a high-
risk population that requires particular attention.
In the Danish Investigations of Arrhythmia and Mortality on
Dofetilide HF (DIAMOND-HF) study, consecutive patients
hospitalized for HF from 1995 to 1996 were screened and 45%
had left ventricular dysfunction, 60% were in New York Heart
Association class III or IV, 38% had previous myocardial
infarction (MI), and 57% had known ischemic heart disease.9 To
put these data in perspective with the current cohort, 50%
qualify for treatment with -blockers, RASi, and spironolactone
and up to 60% for statin treatment, which exceeds the average
level in the present study.1 However, treatment initiation in-
TABLE 2. Average Daily Dosages of the Most Frequently Used RASi, -Blockers, Spironolactone, and Statins in Patients With HF
During Different Periods From Start of Treatment
Average Daily Dosage, mg
Medication %* 0 to 30 d 31 to 180 d 181 to 360 d 3 to 5 y Target Dosage, mg†
Metoprolol‡ 59.4% 75 (50 to 125) 75 (50 to 100) 75 (50 to 100) 75 (50 to 100) 200
Carvedilol 12.1% 12.5 (6.25 to 25) 18.75 (9.37 to 37.5) 25 (12.5 to 50) 25 (12.5 to 50) 50
Bisoprolol 5.5% 5 (3.75 to 10) 5 (2.5 to 7.5) 5 (5 to 10) 5 (5 to 10) 10
Other 23.0%               
RASi
Trandolapril 24.8% 2 (1 to 4) 2 (1 to 3) 2 (1 to 4) 2 (2 to 4) 4
Ramipril 19.8% 5 (3.125 to 7.5) 5 (2.5 to 10) 5 (3.125 to 10) 5 (3.75 to 10) 10
Enalapril 16.0% 10 (7.5 to 20) 10 (5 to 20) 10 (5 to 20) 10 (7.5 to 20) 20
Captopril 11.7% 37.5 (25 to 62.5) 37.5 (25 to 62.5) 37.5 (25 to 62.5) 50 (25 to 62.5) 150
Losartan 9.6% 50 (25 to 75) 50 (25 to 75) 50 (50 to 75) 50 (50 to 75) 50
Candesartan 1.5% 8 (6 to 16) 8 (6 to 16) 8 (8 to 16) 8 (8 to 16) 32
Valsartan 0.6% 120 (80 to 160) 120 (80 to 160) 120 (80 to 160) 80 (80 to 160) 320
Other 16.0%               
Spironolactone 100% 37.5 (25 to 62.5) 37.5 (25 to 50) 25 (25 to 50) 37.5 (25 to 50) 25
Statins
Simvastatin 64.7% 20 (20 to 40) 20 (20 to 40) 20 (20 to 40) 20 (20 to 40) 40
Atorvastatin 15.2% 20 (10 to 20) 20 (10 to 20) 20 (10 to 20) 20 (20 to 40) 80
Prava-
statin
13.0% 40 (20 to 40) 40 (20 to 40) 40 (20 to 40) 40 (20 to 40) 40
Other 7.1%               
Values expressed as median (interquartile range) unless otherwise noted.
*Proportion of all medications within each class, used during the observation time.
†Dosages recommended in guidelines and used in major clinical trials.
‡Mainly metroprolol-succinate.
TABLE 3. Proportion of Patients With HF on RASi, -Blocker, Spironolactone, or Statin Therapy Who Experienced a Break of >7, 30,
90, or 180 Days Within 5 Years of Treatment and the Proportion Who Reinitiated Therapy Within 1 Year After a Break
Proportion Who Experienced a Break
Proportion Who Reinitiated Treatment Within 1 Year After a
Break
Length of Break -Blocker RASi Spironolactone Statin -Blocker RASi Spironolactone Statin
7 days 96.2 95.3 98.0 96.7 91.0 94.1 88.2 97.2
30 days 68.6 59.5 80.7 71.6 73.3 77.9 72.2 91.9

90 days 45.6 36.0 58.5 34.2 47.8 52.5 47.9 74.8
180 days 36.7 27.7 48.7 20.4 27.1 31.0 28.6 45.1
Values are expressed as percentages.
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creased substantially between 1995 and 2004 (Figure 1). This
indicates that physicians increasingly complied with recommen-
dations, along with increased availability of diagnostic methods
to estimate left ventricular ejection fraction (ie, echocardiogra-
phy). Additionally, there was a shift toward -blockers with
documented survival benefit in HF (ie, metoprolol, bisoprolol,
and carvedilol) from 1995 to 2004, but use of other -blockers
probably reflects treatment of concomitant diseases. Notably,
among patients who did not previously receive treatment, the
first prescription was predominantly issued by hospital physi-
cians. This could reflect an initiative during hospitalization,
importance of hospital outpatient clinics, or increased availabil-
ity of dedicated HF clinics in Denmark.
The dosages used were generally below recommended target
dosages (Table 2).1 Also, dosages were rarely uptitrated, with the
exception of the -blocker carvedilol, which was the first
-blocker documented for treatment of HF and primarily pre-
scribed by specialists in cardiology. The dosages of -blockers
and most RASi were 50% or less of recommended dosages.1
Statin dosages were also low, although it is difficult to determine
TABLE 4. Multivariable Cox Proportional Hazard Analysis of Time to First Break in Treatment of >90 Days (Proxy for
Nonpersistence) in HF
-Blockers RASi Spironolactone Statins
Covariate HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
1995 to 1996* 1.00       1.00       1.00       1.00      
1997 to 1998 0.89 0.83 to 0.96 0.004 1.04 0.98 to 1.10 0.24 0.90 0.80 to 0.99 0.04 0.89 0.74 to 1.08 0.25
1999 to 2000 0.80 0.74 to 0.86 0.0001 1.12 1.05 to 1.19 0.0005 0.78 0.71 to 0.85 0.0001 1.10 0.92 to 1.31 0.32
2001 to 2002 0.66 0.61 to 0.71 0.0001 1.04 0.98 to 1.12 0.22 0.78 0.71 to 0.86 0.0001 0.99 0.83 to 1.19 0.92
2003-2004 0.58 0.52-0.64 0.0001 1.02 0.93-1.11 0.73 0.78 0.70 to 0.88 0.0001 0.90 0.73 to 1.09 0.27
Gender
Women* 1.00       1.00       1.00       1.00      
Men 1.06 1.01 to 1.11 0.03 0.95 0.91 to 0.99 0.01 1.20 1.13 to 1.27 0.0001 1.02 0.93 to 1.11 0.70
Age
30 to 59 years* 1.00       1.00       1.00       1.00      
60 to 69 years 1.01 0.94 to 1.08 0.77 1.04 0.97 to 1.11 0.32 1.03 0.94 to 1.12 0.53 0.86 0.77 to 0.95 0.004
70 to 79 years 1.05 0.98 to 1.12 0.14 1.29 1.21 to 1.37 0.0001 1.14 1.05 to 1.23 0.001 0.94 0.84 to 1.05 0.27
80 years 1.01 0.93 to 1.09 0.87 1.48 1.38 to 1.58 0.0001 1.21 1.11 to 1.32 0.0001 1.27 1.08 to 1.50 0.003
Familial status
Living with partner* 1.00       1.00       1.00       1.00      
Living alone 1.06 1.01 to 1.12 0.02 1.08 1.04 to 1.13 0.0003 1.05 0.99 to 1.11 0.08 1.22 1.12 to 1.33 0.0001
Concomitant treatment†
-Blocker          0.92 0.88 to 0.96 0.0001 1.03 0.98 to 1.10 0.26 0.83 0.76 to 0.90 0.0001
RASi 0.89 0.84 to 0.93 0.0001          1.25 1.18 to 1.32 0.0001 0.95 0.87 to 1.03 0.21
Spironolactone 1.01 0.95 to 1.07 0.72 1.19 1.13 to 1.25 0.0001          1.00 0.90 to 1.10 0.98
Statins 0.82 0.77 to 0.87 0.0001 0.86 0.81 to 0.92 0.0001 1.01 0.94-1.08 0.87         
Antidiabetics 0.92 0.86 to 0.99 0.03 0.97 0.92 to 1.03 0.29 1.11 1.03 to 1.19 0.005 0.90 0.81 to 1.01 0.07
Prior treatment† 0.75 0.71 to 0.79 0.0001 0.86 0.83 to 0.90 0.0001 0.69 0.65 to 0.74 0.0001 0.64 0.59 to 0.70 0.0001
Severity group‡
Group I* 1.00       1.00       1.00       1.00      
Group II 1.03 0.98 to 1.10 0.27 1.00 0.94 to 1.06 0.93 0.98 0.89 to 1.07 0.61 0.99 0.89 to 1.09 0.78
Group III 0.97 0.91 to 1.04 0.44 1.04 0.98 to 1.11 0.21 0.85 0.77 to 0.93 0.001 0.86 0.76 to 0.97 0.02
Group IV 1.03 0.93 to 1.13 0.60 1.14 1.05 to 1.24 0.002 0.72 0.64 to 0.81 0.0001 0.80 0.67 to 0.95 0.01
No. of concomitant
drugs§
No concomitant
drug*
1.00       1.00       1.00       1.00      
1 drug 0.95 0.89 to 0.99 0.05 1.06 1.01 to 1.11 0.01 1.27 1.19 to 1.36 0.0001 0.88 0.78 to 0.99 0.05
2 drugs 0.80 0.75 to 0.86 0.0001 0.94 0.89 to 1.01 0.10 1.36 1.26 to 1.48 0.0001 0.82 0.73 to 0.94 0.003
3 drugs 0.75 0.66 to 0.84 0.0001 0.84 0.74 to 0.96 0.01 1.28 1.15 to 1.42 0.0001 0.73 0.62 to 0.86 0.0002
All covariates presented in Table 4 were included in the Cox regression. HR indicates hazard ratio.
*Reference.
†Nonusers as reference.
‡According to average daily dosage of loop-diuretic (furosemide) in the first 90 days after discharge (Group I, 0 to 39 mg; Group II, 40 to 80 mg; Group III, 81 to
160 mg; Group IV, 160 mg).
Interaction with age (P0.0001); age-stratified analysis showed no difference among patients 75 years old (P for trend0.23).
§Additional proportional-hazard model where concomitant drugs were left out.
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the correct dosage because we lack information on lipid levels.
However, because clinical trials comprise selected populations,
the current results may therefore reflect dosages generally used
in an unselected HF population.
After 5 years of treatment, 79% of patients were still on RASi,
65% were on -blockers, 56% were on spironolactone, and 83%
were on statins (Figure 3). Breaks in therapy were common, but
patients who experienced breaks of shorter duration usually
reinitiated therapy (Table 3). Even for breaks of 90 days or
longer, 50% reinitiated treatment within 1 year. This clearly
demonstrates that breaks in treatment are a dynamic factor, in
contrast to many studies that consider a break in treatment
equivalent to discontinuation of treatment. Notably, persistence
of -blocker and spironolactone treatment improved during the
study period (Table 4) along with an increasing number of
patients who initiated treatment. Gender differences were re-
flected in poorer RASi persistence among women, who more
often experience cough,10 and lower spironolactone persistence
among men, who often experience gynecomasty.11 Increasing
age was associated with lower persistence of RASi, spironolac-
tone, and statin treatment, and patients who lived alone also had
generally lower persistence of treatment. Poorer persistence of
statin treatment in elderly patients could relate to socioeconomic
factors, because statins were still fairly expensive during the
study period. Risk of renal side effects and hyperkalemia in older
patients could explain low persistence for treatment with RASi
or spironolactone, as well as for combination treatment with
RASi and spironolactone in this population.12 Notably, an
increased number of concomitant medications was associated
with persistence of treatment, an important finding because
treatment of HF often involves polypharmacy. Also, increased
severity of HF did not worsen persistence, in contrast to studies
that demonstrated risk–treatment mismatch in the pharmacother-
apy of HF.13 This is in accordance with other studies, which
have found no association between HF functional class or
number of concomitant medications and poorer persistence.5,14
Comprehensive studies on persistence of pharmacotherapy in
HF are sparse. Most studies comprise small selected cohorts
with short follow-up, and differences in methods, definitions,
and outcomes make direct comparison difficult. Studies on
different HF populations demonstrate long-term compliance
with RASi to be between 56% and 92%.5,15,16 One study
reported 5-year compliance with angiotensin-converting enzyme
inhibitor to be 75% and with -blockers to be 53%.17 In a cohort
that attended HF clinics only, 10% of patients discontinued
-blocker treatment after 2 years,18 and in another similar study
34% discontinued spironolactone within 1 year.19 In a study on
HF patients in clinical practice, 77% of patients were on
-blockers after 1 year, and importantly severity of HF did not
increase discontinuation of -blocker treatment.14 Studies on HF
patients have observed similar underdosing of angiotensin-
converting enzyme inhibitors and -blockers.16,20 In a previous
study of treatment after MI in Denmark, the persistence and
underdosing of treatment was comparable to the present results.8
In the present study only 8.6% of the patients had the diagnosis
of MI at the index HF admission, and 24.3% had any history of
prior MI; thus, similar results from these 2 studies do not reflect
overlapping populations.
Nonpersistence with RASi, -blockers, and statins was asso-
ciated with higher mortality and hence identified a high-risk
group of patients with HF (Table 5). There is a possibility that
increased mortality was partly caused by confounding-by-
indication (ie, sicker patients could not tolerate medication and
therefore discontinued treatment, shortly before death). How-
ever, we used conservative measures of nonpersistence in our
analysis where only breaks in treatment of 90 days were
considered as risks. Thus patients who died after a shorter break
in therapy were censored in the mortality analyses, which
thereby avoids the possibility that patients who stopped treat-
ment because of increased morbidity in the proximity of death
would bias the relative risk estimates. Another possible expla-
nation of worse prognosis in patients who had breaks in
treatment is “the healthy adherer effect” (ie, patients who have
better persistence of treatment also have healthier lifestyles than
patients with poorer persistence, and therefore good persistence
of treatment is a surrogate marker for overall healthier behav-
ior).21 The Candesartan in Heart Failure: Assessment of Reduc-
tion in Mortality and Morbidity (CHARM) trial demonstrated
that patients with good compliance with either candesartan or
placebo had equal prognosis, and all patients with poor compli-
ance had worse prognosis.5 Ho et al reported almost 4-fold
increased mortality in patients who discontinued treatment after
MI and nonadherence increased mortality and hospitalization
rates in patients with diabetes.22,23 Newby et al found that, in
patients with coronary heart disease and HF, consistent treatment
Figure 3. Long-term persistence with RASi, -blocker, spirono-
lactone, or statin in patients with HF: the proportion of patients
alive who were on treatment on each day.
TABLE 5. Multivariable Cox Proportional Hazard Analysis of
Risk of Death Related to Nonpersistence With Pharmacological
Treatment (Break in Treatment >90 Days) in HF
Drug HR* 95% CI P
RASi 1.37 1.31 to 1.42 0.0001
-Blocker 1.25 1.19 to 1.32 0.0001
Spironolactone 0.95 0.89 to 1.00 0.07
Statins 1.88 1.67 to 2.12 0.0001
*Adjusted for age, year, sex, concomitant medical treatment, severity
(loop-diuretic dosage), and comorbidity.
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with angiotensin-converting enzyme inhibitors was associated
with a 25% reduction in mortality.15 Also, consistent use of
-blockers and lipid-lowering drugs reduced mortality by 37%
and 48%, respectively, but were not analyzed separately for HF.
Furthermore, Rasmussen et al found that the healthy adherer
effect did not explain all of the mortality difference between
high- and low-adherence post-MI patients.24 This certainly
reflects effects far beyond that of simple treatment withdrawal,
thus the term “compliance” is an integrated measure of the entire
clinical situation. It is intriguing that nonpersistence with spi-
ronolactone is not associated with increased mortality. In the
Randomized Aldactone Evaluation Study (RALES), spironolac-
tone treatment reduced mortality in severe HF by 30%.11 But
later studies have demonstrated increased risk of hyperkale-
mia12,19 and increased mortality associated with spironolactone
treatment in chronic HF,25 which could explain why the benefit
of spironolactone treatment is not reflected in increased mortal-
ity in nonpersistent patients.
We observed a decrease in in-hospital mortality, which is
intriguing because there were no major improvements in
acute HF treatment during the study period. This could be a
carry-over effect of increased focus on the treatment of
chronic HF, or reflecting improvements in treatment of other
important cardiovascular diseases such as acute MI.
Strengths and Limitations
The completeness of data, which enables comprehensive
follow-up for 10 years, is the main strength of the study. The
Danish National Patient Registry keeps records on discharge
diagnosis from all hospitals in Denmark, and the present study
thus avoids selection bias, which may be present in surveys that
are based on selected centers. Furthermore, the national prescrip-
tion registry includes all prescriptions dispensed nationwide. Use
of registries to estimate refilling of prescriptions is a reliable
method to estimate long-term persistence,26 avoids recall bias,
and, because there is copayment of the medication expenses,
claimed prescriptions from pharmacy indicates intention to take
the medication. The Danish healthcare system is government-
financed, which secures equal access to health care for all
inhabitants free of charge, regardless of socioeconomic status.
Similar to many Western countries, drug expenses are partially
reimbursed; therefore, we believe the results can be extended to
other countries. But, because persistence of treatment is highly
influenced by copayment of drug expenses,27 lower persistence
of treatment cannot be excluded in healthcare systems in which
copayments are higher.
There are some important limitations of the study that need to
be acknowledged. The diagnosis of HF in the Danish National
Patient Registry has not been validated and, because the diffi-
culties in defining HF are evident, one may question the
precision of the ICD-10 codes used in the present study. Two
recent studies from Scotland and Canada found high accuracy of
the discharge coding diagnosis of HF.28,29 Hence, when the
diagnosis of HF is established, it is accurate. The present study
is based on administrative registries and do not include clinical
data. Thus, precise indications and contraindications for HF
treatments are not available (eg, information on left ventricular
ejection fraction, which often is used for prognostic and man-
agement stratification). Furthermore, contraindications for treat-
ment, adverse reactions, or allergies that might have caused lack
of initiation or early termination are not included in the regis-
tries, which makes it difficult to state which fraction of the
patients who would require therapy in an ideal setting. However,
these limitations are particularly relevant to any attempt to study
the fraction of patients who require therapy, but are not impor-
tant in a study of treatment persistence, dosing, and changes over
time, because patients started on medical therapy were consid-
ered to have the indication for treatment by the caring physician.
Discontinuation of therapy can be caused by several factors,
such as the decision of a caring physician to stop treatment in a
patient with terminal heart failure who is approaching palliative
care or that the patient is too weak to tolerate the treatment.
Conclusions and Clinical Implications
Persistence of treatment was high once treatment was started,
but the dosages used were below recommended dosages.
Particularly, increased severity of HF or increased number of
concomitant medications was not associated with lower
persistence. Nonpersistence with RASi, -blockers, and st-
atins in HF identifies a high-risk population of patients that
requires special attention.
Therefore, hospital departments that care for patients with HF
should consider early in the management which treatment is
indicated for the individual patient and preferably start treatment
before discharge. Furthermore, to ensure appropriate long-term
management, physicians who treat HF patients need to ensure
that treatment is uptitrated to recommended dosages after dis-
charge to achieve maximal benefits of treatment. Once medica-
tion is stable, treatment will continue for many years and patient
can be followed by a general practitioner, but nonpersistence
with treatment might indicate the need for special attention from
a specialist. Thus, a systematic effort to increase initiation of
therapy and ensure titration to appropriate dosages is likely to
provide major long-term benefit.
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CLINICAL PERSPECTIVE
Underuse of evidence-based pharmacotherapy is common in patients with heart failure and may worsen the prognosis.
Studies on the nature of underuse are therefore important to identify likely targets for improvement. We studied the use
and persistence of use of evidence-based pharmacotherapy in 107 092 patients discharged after first hospitalization for
heart failure in Denmark between 1995 and 2004. Furthermore, we studied the association between persistence and
long-term prognosis. The present study demonstrated that if treatment was started early after discharge, most patients
continued treatment for long-term. If treatment was not started early after discharge, the likelihood of ever receiving
treatment was low. Short breaks in treatment were common, but most patients reinitiated treatment, especially after short
breaks. Treatment dosages were in general only 50% of recommended dosages and were not increased during long-term
treatment. Five years after initiation of treatment, 79% of patients were still on angiotensin-converting enzyme inhibitors
and angiotensin-receptor blockers, 65% on -blockers, 56% on spironolactone, and 83% on statins. Notably, multiple drug
treatment and increased severity of heart failure was not associated with poorer persistence of treatment. Nonpersistence
with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, -blockers, and statins identified a
high-risk population who required special attention and was associated with increased mortality. Therefore, hospital
departments that care for patients with heart failure should consider early in the management of these patients which
treatments are indicated and make arrangements for both initiation of treatment and uptitration. A focused effort on early
treatment initiation, appropriate dosages, and persistence is likely to provide long-term benefit.
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